Lv1
58 积分 2025-02-10 加入
BEHAVIOURAL SIDE EFFECTS OF ATROPINE EYE DROPS
1天前
求助中
Niraparib/olaparib
7天前
已完结
Niraparib
7天前
已完结
Unresolved issues with efgartigimod in CIDP, and broader concerns for future trial design
8天前
已完结
Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics network study (Ophthalmol Retina. 2024;8:733–743)
13天前
已关闭
Infographic: Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: ALTAIR study
14天前
已完结
Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies: A World Health Organization Pharmacovigilance Study
14天前
已完结
Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics network study (Ophthalmol Retina. 2024;8:733-743.)
15天前
已关闭
Blind Spots in Therapy: Unveiling Drug-Induced Angle-Closure Glaucoma Through a National Analysis
15天前
已完结
Infographic: Ranibizumab plus panretinal photocoagulation (PRP) versus PRP alone for high-risk proliferative diabetic retinopathy (PDR): the PROTEUS study
15天前
已完结
皖公网安备34019202002308
